Low vitamin B-12 status in confirmed Alzheimer's disease as revealed by serum holotranscobalamin.
OBJECTIVE
To examine the possible association of holotranscobalamin, the active fraction of serum cobalamin, with Alzheimer's disease.


METHODS
51 patients with pathologically confirmed Alzheimer's disease and 65 cognitively screened elderly controls were studied. Serum holotranscobalamin was measured by a new solid phase radioimmunoassay.


RESULTS
Geometric mean levels showed no significant case-control differences for serum total cobalamin, but lower levels of holotranscobalamin in Alzheimer's disease (41.1 pmol/l) than in controls (57.1 pmol/l) (p < 0.001). The odds ratio of Alzheimer's disease was significant for low holotranscobalamin but not for low total cobalamin.


CONCLUSIONS
Disturbed cobalamin status is common in Alzheimer's disease and accordingly measurement of holotranscobalamin should be considered in the assessment of cognitively impaired patients.
Refsum
H
H
Department of Pharmacology, University of Oxford, Oxford, UK.
Smith
A D
AD
D000368:Aged; D000544:Alzheimer Disease / Q000150:complications*; D005260:Female; D006801:Humans; D008297:Male; D011863:Radioimmunoassay; D014155:Transcobalamins / Q000032:analysis*; D014805:Vitamin B 12 / Q000097:blood*; D014806:Vitamin B 12 Deficiency / Q000503:physiopathology*
D014155:Transcobalamins; D014805:Vitamin B 12